IceCure Medical Ltd. Reports Preliminary Q2 2025 Sales
Ticker: ICCM · Form: 6-K · Filed: Jul 10, 2025 · CIK: 1584371
Sentiment: neutral
Topics: preliminary-results, sales-update, financials
TL;DR
IceCure's Q2 sales hit $525K, six-month sales $1.25M, due to shipment delays.
AI Summary
IceCure Medical Ltd. reported preliminary unaudited financial information for the periods ending June 30, 2025. Product sales for the three months ended June 30, 2025, were approximately $525,000, and for the six months ended June 30, 2025, product sales were approximately $1.25 million. The company cited delayed shipments and lower sales as contributing factors.
Why It Matters
This filing provides early insight into IceCure's revenue performance, indicating potential challenges with sales and shipments in the second quarter of 2025.
Risk Assessment
Risk Level: medium — The preliminary nature of the financial information and the mention of delayed shipments and lower sales suggest potential headwinds for the company.
Key Numbers
- $525,000 — Product Sales (3-month period) (Preliminary sales for the three months ended June 30, 2025.)
- $1.25 million — Product Sales (6-month period) (Preliminary sales for the six months ended June 30, 2025.)
Key Players & Entities
- IceCure Medical Ltd. (company) — Filer of the report
- $525,000 (dollar_amount) — Product sales for the three months ended June 30, 2025
- $1.25 million (dollar_amount) — Product sales for the six months ended June 30, 2025
- June 30, 2025 (date) — Reporting period end date
FAQ
What were the specific reasons for the delayed shipments mentioned in the filing?
The filing mentions delayed shipments and lower sales but does not provide specific reasons for these delays.
When will the final audited financial statements for the period ending June 30, 2025, be released?
The filing does not specify a date for the release of the final audited financial statements.
What is the company's outlook for the remainder of 2025, given the preliminary sales figures?
The filing does not provide an outlook for the remainder of 2025.
Are the preliminary financial figures expected to change significantly upon final audit?
The filing does not indicate whether the preliminary figures are expected to change significantly.
What product lines contributed to the reported sales of $525,000 and $1.25 million?
The filing does not break down the sales by product line.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 10, 2025 regarding IceCure Medical Ltd. (ICCM).